Added to YB: 2026-10-14
Pitch date: 2026-10-11
NOVO-B.CO [bullish]
Novo Nordisk A/S
+2.45%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 257.15
Price Target
N/A
Dividend
4.56%
EV/EBITDA
7.01
P/E
9.79
EV/Sales
3.73
Sector
Pharmaceuticals
Category
turnaround
Top 5 European Stocks October 2026 - Novo Nordisk A/S
NOVO-B.CO (monitor): Novo Nordisk at roughly DKK250 appears priced for permanent decline despite rising GLP-1 volumes, two 2026 guidance upgrades, a 44.6% H1 operating margin and restructuring savings above DKK10B. Trailing published P/E is below 10x, though earnings are boosted by a provision reversal, and buybacks averaged DKK281. The turnaround remains unproven, with U.S. revenue at risk if falling net prices erase volume growth and Eli Lilly's Zepbound leading Wegovy in expected 2026 sales.
Read full article (3 min)